Clinical Trials
17 trialsNCT05558904 2025-11-10
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT01737502 2025-09-05
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04046614 2024-02-06
NintNivo
AIO-Studien-gGmbH
Phase 1/2 Completed
NCT05079022 2021-10-15
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
Phase 1/2 Unknown
NCT03298763 2021-04-28
TACTICAL
University College, London
Phase 1/2 Unknown
NCT03361319 2020-11-24
N3
Royal Marsden NHS Foundation Trust
Phase 1/2 Withdrawn
NCT01259089 2019-09-11
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Northwestern University
Phase 1/2 Completed
NCT02466568 2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT00547443 2019-01-10
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00003202 2018-08-10
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT00728845 2017-05-23
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT00471835 2017-01-19
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1/2 Withdrawn
NCT00716456 2015-04-30
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02044601 2014-04-24
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00268255 2013-04-16
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn